Assessment | V0 | V1 | V2 | V3 | Early termination | ||
---|---|---|---|---|---|---|---|
Time point | Baseline (-14 ~ 0 day) | 0 day | 12 weeks ± 7 days | 24 weeks ± 7 days |  | ||
Informed consent | × |  |  |  |  | ||
Inclusion/exclusion | × |  |  |  |  | ||
Randomization |  | × |  |  |  | ||
Demographic data | × |  |  |  |  | ||
Physical examinationa | × |  | × | × | × | ||
Medical history collection | × |  |  |  |  | ||
History of allergies to this study ingredients | × |  |  |  |  | ||
Concomitant medication | × |  |  |  |  | ||
Dietary habits, smoking, and alcohol consumption survey | × |  |  |  |  | ||
PAR-Q+ | × |  |  |  |  | ||
Laboratory examinationb | × |  | × | × | × | ||
Hepatitis panelc | × |  |  |  |  | ||
Serum β - human cborionic gonadotropin test (for reproductive-age female) | × |  | × | × | × | ||
72-hour dietary record | × |  | × | × | × | ||
Electrocardiogram | Â | Perform electrocardiogram when necessary | Â | ||||
Abdominal QCT (intrahepatic content of lipid) | × |  | × | × | × | ||
Body composition | × |  | × | × | × | ||
Muscle strengthd | Â | Â | Â | Â | Â | ||
Gut flora and the gut hormonee | × |  | × | × | × | ||
Adherence |  |  | × | × | × | ||
The occurrence of adverse events |  |  | × | × | × | ||
Follow up summary |  |  | × | × | × |